Avant CholeraGarde preliminary Phase II data

AVAN said a preliminary analysis of a Phase II trial to prevent cholera showed that a single dose of CholeraGarde ( Peru-15) vaccine met the co-primary endpoints of safety and immunogenicity. In the d...